Hydrogenuhličitan Sodný B. Braun

Hydrogenuhličitan Sodný B. Braun is a sodium hydrogen carbonate solution for injection, supplied in a sterile liquid form for intravenous administration. The product contains the active ingredient sodium hydrogen carbonate, which acts as an antacid and electrolyte replenisher. It is marketed in the European Union and requires a prescription. The preparation is used to correct acid‑base disturbances and to alkalinize urine in clinical settings under medical supervision.

Hydrogenuhličitan Sodný B. Braun is indicated for several clinical situations that require rapid correction of systemic acidity or urine alkalinization.

- Treatment of metabolic acidosis associated with renal failure, diabetic ketoacidosis, or severe diarrhea. - Management of other acid‑base disorders where bicarbonate supplementation is required. - Alkalinization of urine to facilitate excretion of certain toxins or to prevent crystallization of drugs such as methotrexate. - Use during cardiopulmonary bypass or massive transfusion when electrolyte balance and pH need stabilization. - Adjunct therapy in patients receiving high doses of salicylates or other acids.

Adverse reactions to intravenous sodium hydrogen carbonate are generally related to rapid shifts in plasma pH and electrolyte balance.

Common: - Transient mild hypernatremia. - Temporary metabolic alkalosis with elevated blood pH. - Local irritation at the infusion site, such as pain or erythema. - Mild headache or dizziness. - Mild nausea or vomiting. - Flushing or feeling of warmth. - Transient increase in blood pressure.

Serious: - Severe metabolic alkalosis leading to respiratory depression. - Cardiac arrhythmias associated with rapid changes in serum potassium. - Hypocalcemia secondary to increased binding of calcium to bicarbonate. - Pulmonary edema in patients with fluid overload. - Seizures due to severe alkalosis. - Renal vasoconstriction leading to decreased renal perfusion.

When prescribing Hydrogenuhličitan Sodný B. Braun, clinicians should evaluate patient-specific factors that may increase the risk of complications.

- Assess baseline arterial blood gas and serum electrolytes before administration. - Use caution in patients with renal insufficiency or chronic kidney disease. - Avoid rapid infusion rates that could precipitate severe alkalosis. - Monitor cardiac rhythm in individuals prone to arrhythmias or receiving potassium‑depleting drugs. - Limit use in patients with congestive heart failure or fluid overload. - Re‑evaluate pH and bicarbonate levels during and after therapy to guide further dosing. - Consider alternative buffering agents in pregnant or lactating women when safety data are limited.

Intravenous sodium hydrogen carbonate may affect the pharmacokinetics or pharmacodynamics of several concomitant medications.

Avoid: - Concurrent high‑dose salicylates, which can increase the risk of metabolic alkalosis. - Co‑administration with calcium‑containing solutions that may precipitate calcium carbonate. - Simultaneous use of loop diuretics that cause rapid potassium loss, heightening arrhythmia risk. - Combination with bicarbonate‑rich oral antacids, which can cause excessive systemic alkalinity.

Use with caution: - Drugs that are pH‑dependent for absorption or excretion, such as methotrexate, may require dose adjustment. - Anticoagulants, because changes in plasma pH can alter clotting factor activity. - Beta‑agonists, as alkalosis may potentiate their cardiovascular effects. - Administration with insulin therapy, as rapid correction of acidosis may alter glucose utilization.